Trade Summary

5 days ago, Connaughton Bernadette, serving as Dir at Halozyme Therapeutics, Inc. (HALO), sold 1,625 shares at $63.48 per share, for a total transaction value of $103,155.00. Following this transaction, Connaughton Bernadette now holds 38,498 shares of HALO.

This sale represents a 4.00% decrease in Connaughton Bernadette's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Friday, May 1, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, May 5, 2026, 4 days after the trade was made.

Halozyme Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.